FGFR1 and osteochondrodysplasia: Since the osteochondrodysplasia phenotype is driven by overactivation of the FGFR1 receptor, we evaluated the effect of infigratinib, a small molecule tyrosine kinase inhibitor against FGFR1–3 activity in vitro and in vivo.